Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-13
2007-03-13
Rawlings, Stephen L. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388260, C530S388800, C530S328000, C530S350000
Reexamination Certificate
active
11133177
ABSTRACT:
Proteins useful in the diagnosis of proliferative disorders of the colon are present in nuclear matrix protein preparations and can be characterized by molecular weight, isoelectric point, and amino acid sequence. The proteins may be identified, for example, by 2D-gel electrophoresis or by specific binding partners, such as antibodies.
REFERENCES:
patent: 4161519 (1979-07-01), Talwar
patent: 4608251 (1986-08-01), Mia
patent: 5547928 (1996-08-01), Wu et al.
patent: RE35747 (1998-03-01), Penman et al.
patent: 5824490 (1998-10-01), Coffey et al.
patent: 5830677 (1998-11-01), Wu et al.
patent: 5989826 (1999-11-01), Beausang et al.
patent: 6162608 (2000-12-01), Beausang et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 6410247 (2002-06-01), Beausang et al.
patent: WO 99/62942 (1999-12-01), None
patent: WO 00/65069 (2000-11-01), None
Balasubramani et al. (Cancer Res. Jan. 2006; 66 (2): 763-769).
Sistermans et al. (Cell Tissue Res. 1995; 280; 435-446).
Holmes (Expert Opinion on Investigational Drugs. 2001; 10; 511-519).
Brünagel et al., “Nuclear Matrix Protein Alterations Associated with Colon Cancer Metastasis to the Liver,”Clinical Cancer Research, Oct. 2002, pp. 3039-3045, vol. 8.
Coffey, “Nuclear Matrix Proteins as Proteomic Markers of Preneoplastic and Cancer Lesions,” Commentary re: G. Brunagel et al., Nuclear Matrix Protein Alterations Associated with Colon Cancer Metastasis to the Liver. Clin. Cancer Res., 8:3039-3045, 2002,Clinical Cancer Research, Oct. 2002, pp. 3031-3033, vol. 8.
Ahlquist, “Fecal Occult Blood Testing for Colorectal Cancer,”Gastroenterology Clinics of North America, Mar. 1997, pp. 41-55, vol. 26, No. 1, W.B. Saunders Company.
Berezney et al., “Identification of a Nuclear Protein Matrix,”Biochemical and Biophysical Research Communications, Oct. 23, 1974, pp. 1410-1417, vol. 60, No. 4, Academic Press, Inc.
Boyd et al., “Preneoplastic Alterations in Nuclear Morphology That Accompany Loss of Tumor Suppressor Phenotype,”Journal of the National Cancer Institute, Jun. 19, 1991, pp. 862-866, vol. 83, No. 12.
Brünagel et al., “Identification of Nuclear Matrix Protein Alterations Associated with Human Colon Cancer,”Cancer Research, Apr. 15, 2002, pp. 2437-2442, vol. 62, No. 8, American Association for Cancer Research.
Carriquiry et al., “Should Carcinoembryhonic Antigen be Used in the Management of Patients with Colorectal Cancer,”Diseases of the Colon Rectum, Jul. 1999, pp. 921-929, vol. 42, No. 7, Lippincott Williams & Wilkins.
Cupo, “Electrophoretic analysis of nuclear matrix proteins and the potential clinical applications,”Journal of Chromatography, Sep. 13, 1991, pp. 389-406, vol. 569, Nos. 1 & 2, Elsevier Science Publishers B.V., Amsterdam.
Douillard et al., “Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors,”Hybridoma, 1986, pp. S139-S149, vol. 5, Supp. 1, Mary Ann Liebert, Inc., New York.
Fey et al., “Nuclear matrix proteins reflect cell type of origin in cultured human cells,”Proc. Natl. Acad. Sci. USA, Jan. 1988, pp. 121-125, vol. 85, Cell Biology.
Fey et al., “The Nuclear Matrix: Defining Structural and Functional Roles,”Critical Reviews in Eukaryotic Gene Expression, 1991, pp. 127-143, vol. 1, Issue 2, CRC Press, Inc.
Geenen et al., “Major Complications of Coloscopy: Bleeding and Perforation,”Digestive Diseases, Mar. 1975, pp. 231-235, vol. 20, No. 3.
Getzenberg et al., “Bladder Cancer-associated Nuclear Matrix Proteins,”Cancer Research, Apr. 1, 1996, pp. 1690-1694, vol. 56, No. 7.
Getzenberg et al., “Identification of Nuclear Matrix Proteins in the Cancer and Normal Rat Prostate,”Cancer Research, Dec. 15, 1991, pp. 6514-6520, vol. 51, No. 24.
Getzenberg et al., “Nuclear Matrix and the Regulation of Gene Expression: Tissue Specificity,”Journal of Cellular Biochemistry, May 1994, pp. 22-31, vol. 55, No. 1, Wiley-Liss, Inc.
Getzenberg et al., “The Tissue Matrix: Cell Dynamics and Hormone Action,”Endocrine Reviews, Aug. 1990, pp. 399-417, vol. 11, No. 3, The Endocrine Society, USA.
Gevaert et al., “New Strategies in High Sensitivity Characterization of Proteins Separated from 1-D or 2-D Gels,”Methods in Protein Structure Analysis, 1995, pp. 15-25, Plenum Press, New York, USA.
Godreau, “Office-Based Colonoscopy in a Family Practice,”Family Practice Research Journal, Sep. 1992, pp. 313-321, vol. 12, No. 3, Human Sciences Press, Inc., New York.
Goeddel, “Systems for Heterologous Gene Expression,”Methods in Enzymology, 1990, pp. 3-7, vol. 185, Academic Pres, Inc.
Goldenberg et al., “Carcinoembryonic Antigen in Histopathology: Immunoperoxidase Staining of Conventional Tissue Sections,”J. Natl. Cancer Inst., Jul. 1976, pp. 11-22, vol. 57, No. 1.
Greenlee et al., “Cancer Statistics, 2000,”A Cancer Journal for Clinicians, Jan./Feb. 2000, pp. 7-33, vol. 50, No. 1, American Cancer Society.
Harlow et al. (Eds.),Antibodies: A Laboratory Manual, 1988, Cold Spring Harbor Laboratory.
Hermanson (Ed.),Bioconjugate Techniques, 1996, (Table of Contents Only), Academic Press, Inc., San Diego, CA.
Herrera et al., “Carcinoembryonic Antigen (CEA) as a Prognostic and Monitoring Test in Clinically Complete Resection of Colorectal Carcinoma,”Annals of Surgery, Jan. 1976, pp. 5-9, vol. 183, No. 1, J.B. Lippincott Company.
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” Proc. Natl. Acad. Sci. USA, Aug. 1998, pp. 5879-5883, vol. 85.
Kabat et al. (Eds),Sequences of Proteins of Immunological Interest, 4thEdition, 1987 (Table of Contents Only), U.S. Department of Health and Human Services.
Keesee et al., “Nuclear matrix proteins in human colon cancer,”Proc. Natl. Acad. Sci. USA, Mar. 1994, pp. 1913-1916, vol. 91.
Keesee et al., “Utilization of Nuclear Matrix Proteins for Cancer Diagnosis,”Critical Reviews in Eukaryotic Gene Expression, 1996, pp. 189-214, vol. 6, Issues 2 & 3, Begell House, Inc.
Konety et al., “Identification of Nuclear Matrix Protein Alterations Associated with Renal Cell Carcinoma,”The Journal of Urology, Apr. 1998, pp. 1359-1363, vol. 159, No. 4, American Urological Association, Inc.
Martell et al., “OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders,”The International Journal of Biological Markers, Jul.-Sep. 1998, pp. 145-149, vol. 13, No. 3, Wichtig Editore—Milano, Italy.
Merrifield, “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,”J. Am. Chem. Soc., Jul. 20, 1963, pp. 2149-2154, vol. 85.
Miller et al., “Detection of Nuclear Matrix Proteins in Serum from Cancer Patients,”Cancer Research, Jan. 15, 1992, pp. 422-427, vol. 52, No. 2.
Moertel et al., “An Evaluation of the Carcinoembryonic Antigen (CEA) Test for Monitoring Patients With Resected Colon Cancer,”JAMA, Aug. 25, 1993, pp. 943-947, vol. 270, No. 8.
Patton et al., “Development of a Dedicated Two-Dimensional Gel Electrophoresis System that Provides Optimal Pattern Reproducibility and Polypeptide Resolution,”BioTechniques, May 1990, pp. 518-527, vol. 8, No. 5.
Replogle-Schwab et al., “The Utilization of Nuclear Matrix Proteins for Cancer Diagnosis,”Critical Reviews in Eukaryotic Gene Expression, 1996, pp. 103-113, vol. 6, Issues 2 & 3, Begell House, Inc.
Reynoso et al., “Carcinoembryonic Antigen in Patients with Different Cancers,”JAMA, Apr. 17, 1972, pp. 361-365, vol. 200, No. 3.
Stewart et al. (Eds.), “Chapter 2, Laboratory Techniques in Solid Phase Peptide Synthesis,”Solid Phase Peptide Synthesis, 1969, pp. 27-64, W.H. Freeman and Company.
Uhlén et al., “Gene Fusions for Purpose of Expression:
Bauer Anthony J.
Bruenagel Gisela
Getzenberg Robert H.
Schoen Robert E.
Rawlings Stephen L.
University of Pittsburgh
LandOfFree
Antibody against illfdyfnr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody against illfdyfnr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody against illfdyfnr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3799903